Company intelligence / Profile preview

Occutrack

Ownership: Private
Development stage: Preclinical

Overview

Occutrack has developed a home-based, AI-powered eye movement tracking system for remote monitoring of age-related macular degeneration. The system enables self-administered vision tests with real-time results, reducing the need for frequent clinic visits. Supported by over 30 doctors and two completed clinical trials, the technology is currently undergoing further interventional studies and seeking regulatory approval[3][4].

Therapeutic areas: Ophthalmology
Modalities: DeviceDigital health platformAI-based diagnostic tool
Industry: Physiological Monitoring

Partnerships

Supported by over 30 doctors in clinical trials; spin-off relationships with A*Star (Agency for Science, Technology and Research), National Healthcare Group Singapore (NHG), Trendlines Medical Company

Beyond the preview

Go deeper on Occutrack.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Occutrack.

Explore the full profile